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INTRODUCTION
Magnesium sulfate being an N‑methyl‑d‑aspartate receptor 
antagonist has both analgesic and sedative properties and has 
been extensively used in anesthesia in the recent past.[1‑4] Role 
of magnesium sulfate as prophylaxis in severe preeclampsia 
is well‑established.[1‑4] Intravenous (i.v) loading dose followed 
by continuous infusion is another well‑established technique. 
Local anesthetic adjuvants have been studied in an attempt 
to prolong the duration of analgesia after peripheral 
nerve blockade. Magnesium has been shown to have an 
antinociceptive effect in animal and human pain models. i.v 
magnesium sulfate has been shown to significantly prolong 
the duration of analgesia when used as an adjuvant in spinal 
anesthesia for orthopedic cases.[5‑9] Different regimens of the 
loading dose (4 g, 6 g and 2 g) followed by infusion at the rate 
of 1 g/h, 2 g/h, have been tried in the past for prophylaxis of 
severe preeclampsia.[4‑9] Considering the toxicity of magnesium 
sulfate such as renal, central nervous system (CNS), and 
respiratory compromise, low dose magnesium sulfate 
(2 g followed by 1 g/h) is advocated in obstetrics practice.[4‑9]
Severe preeclampsia is defined as sustained elevations 
in systolic blood pressure (BP) to at least 160 mmHg 
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and/or in diastolic BP to at least 110 mmHg for at least 
6 h in association with abnormal proteinuria or if there is 
hypertension in association with severe proteinuria (at least 
5 g/24 h period).[2] Preeclampsia is also considered severe in 
the presence of multi‑organ involvement such as pulmonary 
edema, oliguria (<500 ml/24 h period), thrombocytopenia 
(platelet count <100,000/mm3), abnormal liver enzymes 
in association with persistent epigastric or right upper 
quadrant pain, or persistent severe CNS symptoms (altered 
mental status, headaches, blurred vision, or blindness) even 
if all criteria of definitions are not fulfilled.[2,10,11] Eclampsia 
is the occurrence of seizures in a preeclamptic that cannot 
be attributed to other causes. The seizures are grand mal 
type and may appear before, during, or after labor.[2,10,11]
Intravenously administered magnesium sulfate is effective 
in reducing the incidence of eclampsia in women with 
severe preeclampsia.[2‑7] Magnesium sulfate should be 
considered for women with preeclampsia for whom there is 
concern about the risk of eclampsia, such as hyperreflexia, 
frontal headache, blurred vision, and epigastric 
tenderness.[2‑7] Duration of treatment should not normally 
exceed 24 h, and if the i.v route is used for maintenance 
therapy, the dose should not exceed 1 g/h.[1‑6] Clinical 
monitoring of respiration, tendon reflexes, and urine 
output are enough for monitoring of magnesium toxicity. 
Progression from mild to severe disease and development 
of serious maternal complications during antepartum, 
intrapartum, and postpartum cannot be predicted without 
close maternal surveillance.[2‑9]
Considering the safety profile of this regimen particularly in 
low resource set ups, our study was planned to observe the 
effect of this low dose regimen on prolongation of spinal 
anesthesia and improvement in the analgesic quality for 
cesarean section in these patients.
SUBJECTS AND METHODS
This prospective cross‑sectional double blinded randomized 
controlled trial was conducted in a time period of 1‑year 
in a tertiary care hospital in West Bengal after taking 
Institutional Ethical Clearance and informed consent of 
patients.
Inclusion criteria
Eighty severe preeclamptic mothers scheduled for 
caesarean section under spinal anesthesia were chosen 
for the study. Randomization and sample population 
were derived using computer‑generated Microsoft Excel 
program. Windows Vista, Microsoft Office 2007, Group B 
and BM. Group BM (n = 40) received magnesium sulfate 
40 mg/kg diluted in 100 ml of normal saline administered 
over 15 min about 30 min prior to surgery followed by 
continuous infusion at the rate of 10 mg/kg/h for the next 
24 h, while the other group, Group B (n = 40) received 
similar volume of normal saline in the same manner. All 
patients received loading dose of magnesium sulfate 4 g 
i.v slowly, 5 g i.m in each buttock and labetalol injection 
i.v 20 mg on admission, and patients were monitored 
every 10 min and treated accordingly.
Exclusion criteria
The American Society of Anesthesiologists ≥ III, eclamptic 
patients, body mass index (BMI) ≥35 kg m2 and <18.5, 
reported adverse reactions to any of the drugs included 
in the study, patients with history of ischemic heart 
disease, renal, hepatic and pulmonary diseases, those on 
antipsychotics, anticoagulants, epileptics, diabetics, or on 
any other drug affecting the metabolism of anesthetics 
used, any chronic pain syndrome, thrombocytopenia, 
history of seizures, medication use that affects cytochrome 
P450‑3A4 or P450‑1A2 metabolism (including smokers and 
tobacco addicts).
Preoperative assessment
A thorough clinical history was obtained. They were 
physically examined, laboratory investigations were 
reviewed. The patients were also explained about the 
procedures of anesthesia. The patients were counseled about 
the anesthetic management and potential complications of 
both surgery and anesthesia. The purpose, protocol of the 
study, and use of visual analog scale (VAS) was explained to 
patients. All patients eligible for the trial had the following 
information documented preoperatively: Medication list, 
age, sex, height, weight, BMI, serum urea, fasting sugar, 
creatinine, calculated creatinine clearance (Cockroft–Gault), 
liver function tests (aminotransferase, alkaline phosphatase, 
total bilirubin), serum electrolytes, coagulation profile, 
electrocardiogram, chest X‑ray, primary diagnosis, and 
scheduled procedure.
Airway assessment
Malampatti classification, mouth opening, neck movement, 
altered anatomy of the mouth, thyromental distance, 
Wilson scoring system was noted to find out any possibility 
of difficult intubation. If there is a chance of significant 
difficult intubation, they were excluded from the study. 
Instructions for preoperative fasting were given as per Nil 
per Oral guidelines.
On the day of surgery baseline parameters such as heart rate, 
systolic BP, distolic BP, mean arterial pressure, and oxygen 
saturation were measured (SpO2). An i.v line was started.
Both groups received heavy bupivacaine intrathecally. 
Magnesium sulfate 40 mg/kg diluted in 100 ml of normal 
saline was administered over 15 min about 30 min prior 
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to surgery followed by continuous infusion at the rate 
of 10 mg/kg/h for the next 24 h while the other group 
received similar volume of normal saline in the same 
manner. The drugs were prepared by anesthesiologists 
totally ignorant about the study, and observations 
were made by another group of anesthesiologists and 
obstetricians who were unaware of the type of drug 
received by each patient.
Spinal anesthesia was performed through the L3‑L4 or L4‑L5 
interspace in the lateral decubitus position. After dural 
puncture with a 27 G spinocan needle (Braun, India), hyperbaric 
bupivacaine 0.5% solution was injected intrathecally. 
Intraoperatively, patients were monitored for hemodynamic 
perturbations, respiratory rate, urine output, Apgar score, 
uterine tonicity, and any other adverse effects. Postoperatively, 
duration of analgesia, number of rescue analgesics, signs 
of any magnesium toxicity, and incidence of postpartum 
eclampsia in the first 24 h were recorded.
Pain at rest (i.e. with patient not carrying any activity) was 
evaluated using the 0‑10 cm VAS (0 – No pain at all to 
10 – Worst pain imaginable) at emergence from anesthesia 
and 2, 4, 6, 12, and 24 h after surgery. During first 4 h, the 
patients were in the recovery room, and rescue analgesia 
was provided at VAS > 3 in the form of diclofenac sodium 
75 mg i.m. Sedation was monitored using a four‑point 
rating scale (1 – patient fully awake, 2 – patient somnolent, 
but responds to verbal commands, 3 – patient somnolent, 
but responds to tactile stimulation, 4 – patient asleep, 
but responds to pain). Thereafter, the patients were sent 
to ward and diclofenac sodium 75 mg intramuscularly 
was given on demand. The timing and dosage of rescue 
analgesic and total consumption of diclofenac sodium 
during first 24 h after operation was noted. Postoperative 
nausea and vomiting were reported by obstetricians and 
nursing personnel. Data were analyzed using SPSS version 
16. (SPSS Inc. Released 2007. SPSS for Windows, Version 
16.0. Chicago, SPSS Inc.) P <0.01** was considered as 
highly significant and < 0.05** as significant. Unpaired 
t‑test was used to analyze numerical data [Tables 1‑4] and 
Chi‑square test to analyze categorical data (vomiting and 
shivering).
RESULTS
The demographic profiles, baseline hemodynamic parameters, 
duration of surgery of patients in two groups were 
comparable. Postoperatively, time required for first analgesic 
dose was significantly more in Group BM 270 (35.1) min than 
Group B 223 (31.4) min [Table 1 and Figure 1]. There was a 
significant decrease in total rescue analgesic requirement in 
Group BM 2.5 (0.4) compared to Group B 3.6 (0.4) [Table 1 
and Figure 2]. Patients in Group BM were significantly more 
sedated as compared to Group B patients [Table 2 and 
Figure 3]. At different time intervals, patients in Group BM 
had significant less pain than Group B when compared on 
VAS [Table 3]. None of the patients demonstrated bradycardia, 
hypotensive episodes, hypoxia, or hypoventilation in the 
postoperative period in the recovery room. Intraoperatively, 
Group BM had significant hypotension as compared to 
Group B [Table 4]; but readily correctable with vasopressors. 
There was no significant respiratory depression, Apgar 
score was comparable, and uterine tonicity as reported 
by obstetricians, who were blind to the study drug used, 
was adequate in both the groups. Incidence of postpartum 
eclampsia in study group (one patient) was less than the 
control group (four patients). In group BM, three patients had 
shivering, 4 had postoperative nausea and vomiting, and in 
Group B, eight patients had shivering and 9 had postoperative 
nausea vomiting and the difference between the groups was 
not significant.
Table 1: Time interval of first analgesic requirement and total 
rescue analgesic requirement
Parameter Mean (SD) P
Group BM Group B
Postoperative first requested 
analgesic dose required (min)
270 (35.1) 223.6 (31.40) <0.001**
Total analgesic requirement 
postoperatively (g)
2.5 (0.4) 3.6 (0.4) <0.001**
**P<0.01 (highly significant). SD – Standard deviation
Table 2: Sedation scores of patients in the recovery room
Parameter Mean±SD P
Group BM Group B
Sedation score in the recovery room 
immediately after transferring the patient
2.7 (0.9) 1.4 (0.5) <0.001**
Sedation score in recovery room 2 h after 
shifting the patient
2.6 (0.98) 1.3 (0.5) <0.001**
Sedation score in the recovery room 4 h 
after shifting the patient
1.1 (0.6) 1.2 (0.4) <0.001**
**P<0.01 (highly significant). SD – Standard deviation
Table 3: Assessment of pain in postoperative period (VAS)
Parameter Mean (SD) P
Group BM Group B
2 h after surgery 1.2 (0.7) 1.7 (0.9) <0.001**
4 h after surgery 1.3 (0.8) 1.9 (0.4) <0.001**
8 h after surgery 2.7 (1.3) 3.5 (1.3) <0.001**
16 h after surgery 1.4 (0.7) 2 (0.7) <0.001**
24 h after surgery 0.7 (0.6) 1.3 (0.4) <0.001**
**P<0.01 (highly significant). SD – Standard deviation; VAS – Visual analog scale
Table 4: MAP 30 min and 60 min following administration of 
spinal anesthesia
Parameter Mean (SD) P
Group BM Group B
MAP (30 min after spinal) 80.7 (8) 95.3 (4.3) <0.001**
MAP (60 min after spinal) 98.1 (2.20) 98.8 (1.8) 0.04
**P<0.01 (highly significant). MAP – Mean arterial pressure; SD – Standard deviations
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DISCUSSION
Our study has shown that infusion of magnesium sulfate 
given before induction of anesthesia followed by low dose 
infusion per‑operatively is associated with less postoperative 
pain in severe preeclamptic patients undergoing cesarean 
section under spinal anesthesia. Patients in Group BM 
were significantly more sedated as compared to Group B 
patients. At different time, intervals patients in Group BM 
had significant less pain than Group B when compared 
on VAS. None of the patients demonstrated bradycardia, 
hypotensive episodes, hypoxia, or hypoventilation in the 
postoperative period in the recovery room. Intraoperatively, 
Group BM had significant hypotension as compared to 
Group B.
Lee et al. in 2012[12] enrolled 66 patients undergoing 
arthroscopic rotator cuff repair. Interscalene nerve 
block was performed with 0.5% bupivacaine 20 mL with 
epinephrine (1:200,000) plus either 10% magnesium sulfate 
2 mL (magnesium group) or normal saline 2 mL (saline 
group). The duration of analgesia was longer in the 
magnesium group than in the saline group. The onset 
times and durations of sensory and motor blocks were 
not significantly different between the two groups. They 
concluded that the addition of magnesium sulfate to a 
bupivacaine‑epinephrine mixture for interscalene nerve 
block prolongs the duration of analgesia and reduces 
postoperative pain.
A study was undertaken by Kiran et al. in 2011[1] to study 
efficacy of a single dose of i.v magnesium sulfate to 
reduce postoperative pain in patients undergoing inguinal 
surgery. The patients of magnesium sulfate group (Group‑I) 
received magnesium sulfate 50 mg/kg in 250 ml of isotonic 
sodium chloride solution i.v whereas patients in the 
control group (Group‑II) received same volume of isotonic 
sodium chloride over 30 min preoperatively. Pain in the 
postoperative period was significantly lower in magnesium 
sulfate group in comparison to control group at emergence 
from anesthesia and 2, 4, 6, 12 and 24 h postoperatively.
The studies by Lee et al.[12] and Kiran et al.[1] are not exactly 
the same scenario as this current study but our study also 
demonstrated less requirement of analgesics in patients 
receiving i.v magnesium sulfate as it prolongs the duration 
of analgesia and reduces postoperative pain.
Hwang et al. in 2010[13] conducted a study on 40 patients 
undergoing total hip replacement arthroplasty under spinal 
anesthesia. After the induction of spinal anesthesia, the 
magnesium group (Group M) received magnesium sulfate by 
continuous i.v infusion until the end of surgery. The saline 
group (Group S) received the same volume of isotonic saline 
over the same period. After surgery, a patient‑controlled 
analgesia (PCA) device containing morphine and ketorolac 
was provided for the patients. Postoperative pain scores, PCA 
consumption, and the incidences of shivering, postoperative 
nausea, and vomiting were evaluated immediately after 
surgery and at 30 min, 4, 24, and 48 h after surgery. Serum 
magnesium concentrations were checked before the induction 
of anesthesia, immediately after surgery, and at 1 and 24 h 
after surgery. Postoperative pain scores were significantly 
lower in Group M at 4, 24, and 48 h after surgery. Cumulative 
postoperative PCA consumptions were also significantly lower 
in Group M at 4, 24, and 48 h after surgery. Postoperative 
Figure 1: Time interval of first analgesic requirement
Figure 2: Total rescue analgesic requirement
Figure 3: Sedation score
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magnesium concentrations were higher in Group M, but no 
side‑effects associated with hypermagnesemia were observed. 
Hemodynamic variables and the incidences of shivering, 
nausea, and vomiting were similar in the two groups.
They concluded that i.v magnesium sulfate administration 
during spinal anesthesia improved postoperative analgesia. 
The results of these studies are comparable with the present 
study.
Magnesium may induce hypotension directly by vasodilatation 
as well as indirectly by sympathetic blockade and inhibition of 
catecholamine release. We did observe hypotensive episodes 
in our patients who were readily managed with treated with 
vasopressors. Zarauza et al. in 2000[10] and Tramèr and Glynn 
in 2007[11] observed similar hypotensive episodes following 
use of magnesium sulfate as supplementary analgesic. 
While Kiran et al.[1] observed transient fall in BP at induction 
in both groups which they attributed to use of propofol as 
an induction agent. They did not observe any hypotensive 
episode during the operative period. They used magnesium 
sulfate only as single bolus dose whereas most of the studies 
and our study used magnesium sulfate as subsequent infusion 
also in addition to initial single bolus.
A study was conducted by Elgebaly et al. in 2011[14] on 
105 patients randomly allocated to one of the three groups; 
the control Group B received spinal anesthesia with 10 mg 
of 0.5% heavy bupivacaine, the test Group FB received spinal 
anesthesia with 10 mg of 0.5% heavy bupivacaine plus 25 μg 
of preservative‑free fentanyl and the test Group MB received 
spinal anesthesia with 10 mg of 0.5% heavy bupivacaine along 
with i.v magnesium sulfate. The time required for the first 
postoperative analgesic requirement was significantly more 
in Groups FB and MB, as compared to the control group. 
Perioperative sedation was significantly higher in Group FB 
as compared to Group B and Group MB. Nine patients in 
Group FB had postoperative nausea and vomiting, whereas, 
none of the patients in the control group and the difference 
too was statistically significant. We also noticed decreased 
incidence of postoperative nausea and vomiting in patients 
receiving magnesium sulfate.
CONCLUSION
Preoperative i.v magnesium sulfate, in severe preeclampsia 
not only, reduces the probability of developing peripartum 
eclampsia, but also significantly prolongs the duration of 
analgesia and reduces postoperative analgesic consumption 
without any significant side effects.
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